Cargando…
Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2). MacTel2 is typically differentiated from tamoxifen retinopathy based on the presence of late leakage and mid-phase telangi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892311/ https://www.ncbi.nlm.nih.gov/pubmed/29643783 http://dx.doi.org/10.1159/000485739 |
_version_ | 1783313151796707328 |
---|---|
author | Behrens, Alice Sallam, Ahmed Pemberton, John Uwaydat, Sami |
author_facet | Behrens, Alice Sallam, Ahmed Pemberton, John Uwaydat, Sami |
author_sort | Behrens, Alice |
collection | PubMed |
description | Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2). MacTel2 is typically differentiated from tamoxifen retinopathy based on the presence of late leakage and mid-phase telangiectatic vessels on fluorescein angiography (FA) and the presence of hyperautofluorescence. Unlike MacTel2, tamoxifen retinopathy is known to be a progressive disease and the cessation of tamoxifen results in resolution of retinopathy. We report a unique case of nonproliferative MacTel2 in a 36-year-old Hispanic woman with tamoxifen use and the vision outcome 30 months after cessation of tamoxifen. The FA and optical coherence tomography angiography findings of this patient support the diagnosis of MacTel2, but her cessation of tamoxifen led to partial reversal of the topographic findings and improvement in visual acuity. This patient is also unique in the unusually young age of presentation for MacTel2. Our case supports that there are common pathways in the pathogenesis of tamoxifen retinopathy and MacTel2, and tamoxifen use could potentially accelerate foveal atrophy in patients with MacTel2. |
format | Online Article Text |
id | pubmed-5892311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-58923112018-04-11 Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 Behrens, Alice Sallam, Ahmed Pemberton, John Uwaydat, Sami Case Rep Ophthalmol Case Report Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2). MacTel2 is typically differentiated from tamoxifen retinopathy based on the presence of late leakage and mid-phase telangiectatic vessels on fluorescein angiography (FA) and the presence of hyperautofluorescence. Unlike MacTel2, tamoxifen retinopathy is known to be a progressive disease and the cessation of tamoxifen results in resolution of retinopathy. We report a unique case of nonproliferative MacTel2 in a 36-year-old Hispanic woman with tamoxifen use and the vision outcome 30 months after cessation of tamoxifen. The FA and optical coherence tomography angiography findings of this patient support the diagnosis of MacTel2, but her cessation of tamoxifen led to partial reversal of the topographic findings and improvement in visual acuity. This patient is also unique in the unusually young age of presentation for MacTel2. Our case supports that there are common pathways in the pathogenesis of tamoxifen retinopathy and MacTel2, and tamoxifen use could potentially accelerate foveal atrophy in patients with MacTel2. S. Karger AG 2018-01-17 /pmc/articles/PMC5892311/ /pubmed/29643783 http://dx.doi.org/10.1159/000485739 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Behrens, Alice Sallam, Ahmed Pemberton, John Uwaydat, Sami Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 |
title | Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 |
title_full | Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 |
title_fullStr | Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 |
title_full_unstemmed | Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 |
title_short | Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2 |
title_sort | tamoxifen use in a patient with idiopathic macular telangiectasia type 2 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892311/ https://www.ncbi.nlm.nih.gov/pubmed/29643783 http://dx.doi.org/10.1159/000485739 |
work_keys_str_mv | AT behrensalice tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2 AT sallamahmed tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2 AT pembertonjohn tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2 AT uwaydatsami tamoxifenuseinapatientwithidiopathicmaculartelangiectasiatype2 |